As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Dicerna Pharmaceuticals

  • Friday's Range: $4.69-$5.17
  • 52-Week Range: $4.30-$26.79
  • Friday's Volume: 173,000
  • Three-Month Average Volume: 136,148

Dicerna Pharmaceuticals  (DRNA) , a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the U.S. and internationally. This stock closed up 8% to $5.13 in Friday's trading session.

From a technical perspective, Dicerna Pharmaceuticals ripped sharply higher on Friday with strong upside volume flows. This high-volume move is now quickly pushing shares of Dicerna Pharmaceuticals within range of triggering a big breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out Friday's intraday high of $5.17 a share to its 20-day moving average of $5.32 a share and then once it takes out more near-term resistance levels at $5.52 to $5.60 a share with high volume.

Traders should now look for long-biased trades in Dicerna Pharmaceuticals as long as it's trending above its new 52-week low of $4.30 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 136,148 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $6 to its 50-day moving average of $6.25, or even $6.50 to $7 a share.

Novadaq Technologies

  • Friday's Range: $9.15-$9.79
  • 52-Week Range: $8.53-$17.29
  • Friday's Volume: 225,000
  • Three-Month Average Volume: 372,136

Novadaq Technologies  (NVDQ) , develops, manufactures and markets fluorescence imaging products for use by surgeons in the operating room and other clinical settings in the U.S. and internationally. This stock traded up 6.7% to $9.75 in Friday's trading session.

From a technical perspective, Novadaq Technologies ripped sharply higher on Friday right above some near-term support at $8.88 a share and back above its 20-day moving average $9.41 a share with lighter-than-average volume. This stock has been trending sideways and consolidating over the last two months, with shares moving between $8.53 on the downside and $10.15 on the upside. This high-volume spike higher on Friday is now quickly pushing shares of Novadaq Technologies within range of trigger a near-term breakout trade above the upper-end of its recent sideways trending chart pattern. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $10.02 to $10.06 a share and then above $10.15 a share with high volume.

Traders should now look for long-biased trades in Novadaq Technologies as long as it's trending above its 20-day moving average of $9.41 a share or above Friday's intraday low of $9.15 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 372,136 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day moving average of $10.42 to $11, or even its 200-day moving average of $11.50 to around $12 a share.

Idera Pharmaceuticals

  • Friday's Range: $1.89-$2.14
  • 52-Week Range: $1.50-$4.54
  • Friday's Volume: 2.03 million
  • Three-Month Average Volume: 1.13 million

Idera Pharmaceuticals  (IDRA) , a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of therapeutics for oncology and rare diseases in the U.S. This stock traded up 13.5% to $2.10 in Friday's trading session.

From a technical perspective, Idera Pharmaceuticals exploded sharply higher on Friday right off its 50-day moving average of $1.90 a share with strong upside volume flows. This high-volume rip to the upside has now pushed shares of Idera Pharmaceuticals into breakout territory, after the stock closed above some near-term overhead resistance at $2.08 a share. This move is now starting to push this stock within range of triggering another breakout trade. That trade will trigger if this stock manages to take out Friday's intraday high of $2.14 a share to some more key near-term resistance levels at $2.25 to around $2.40 a share with high volume.

Traders should now look for long-biased trades in Idera Pharmaceuticals as long as it's trending above its 50-day moving average of $1.90 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.13 million shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $2.60 to its 200-day moving average of $2.96, or even $3.20 a share.

ProNAi Therapeutics

  • Friday's Range: $6.23-$7.00
  • 52-Week Range: $5.70-$33.75
  • Friday's Volume: 213,000
  • Three-Month Average Volume: 154,561

ProNAi Therapeutics  (DNAI) , a clinical-stage oncology company, develops and commercializes a class of therapeutics based on its DNA interference technology platform for patients with cancer and hematological diseases. This stock traded up 8.2% to $6.83 in Friday's trading session.

From a technical perspective, ProNAi Therapeutics jumped sharply higher on Friday back above its 20-day moving average of $6.48 a share with above-average volume. This stock has formed a triple bottom chart pattern over the last two months, with shares finding buying interest at $5.85, $5.70 and $5.82 a share. Following that potential bottom, shares of ProNAi Therapeutics have now started to trend to the upside and move back above its 20-day. Market players should now look for a continuation move to the upside in the short-term if this stock manages to take out Friday's intraday high of $7 a share with strong volume.

Traders should now look for long-biased trades in ProNAi Therapeutics as long as it's trending above Friday's intraday low of $6.23 a share or above more near-term support at $6 a share and then once it sustains a move or close above Friday's intraday high of $7 a share with volume that hits near or above 154,561 shares. If that move gets underway soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day moving average of $7.87 to $8.24, or even $8.60 a share.

Versartis

  • Friday's Range: $6.39-$6.99
  • 52-Week Range: $6.17-$22.66
  • Friday's Volume: 203,000
  • Three-Month Average Volume: 167,298

Versartis  (VSAR)  operates as an endocrine-focused biopharmaceutical company in the U.S. This stock traded up 5.3% to $6.96 in Friday's trading session.

From a technical perspective, Versartis spiked sharply higher on Friday right above some near-term support at $6.28 a share with above-average volume. This stock recently formed a triple bottom chart pattern, after shares found some buying interest at $6.17, $6.41 and $6.28 a share. Following that potential bottom, shares of Versartis have now started to rip higher and it's quickly trending within range of triggering a big breakout trade. That trade will trigger if this stock manages to take out Friday's intraday high of $6.99 a share to some more near-term resistance at $7.20 a share with high volume.

Traders should now look for long-biased trades in Versartis as long as it's trending above those triple bottom support levels and then once it sustains a move or close above those breakout levels with volume that hits near or above 167,298 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out is next major overhead resistance levels at $8 to $8.12, or even $8.75 to its 50-day moving average of $8.94 a share.

Medgenics

  • Friday's Range: $4.09-$4.58
  • 52-Week Range: $3.09-$10.25
  • Friday's Volume: 175,000
  • Three-Month Average Volume: 127,207

Medgenics  (MDGN) , a clinical stage medical technology company, engages in the research and development of products in the field of biotechnology and associated medical equipment in the U.S. This stock traded up 10.1% to $4.55 in Friday's trading session.

From a technical perspective, Medgenics ripped sharply higher on Friday right above its 50-day moving average of $3.96 a share and back above its 20-day moving average of $4.19 a share with above-average volume. This stock has been uptrending strong over the last two months, with shares moving higher off its new 52-week low of $3.09 a share to its recent high of $4.73 a share. During that uptrend, shares of Medgenics have been making mostly higher lows and higher highs, which is bullish technical price action. This high-volume spike to the upside is now quickly pushing shares of Medgenics within range of triggering a near-term breakout trade. That trade will trigger if this stock manages to take out Friday's intraday high of $4.58 a share to some more key resistance at $4.73 a share with high volume.

Traders should now look for long-biased trades in Medgenics as long as it's trending above its 20-day moving average of $4.19 a share or above its 50-day moving average of $3.96 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 127,207 shares. If that breakout materializes soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at around $5.50 to $6, or even its 200-day moving average of $6.40 a share.

ImmunoGen

  • Friday's Range: $7.21-$7.78
  • 52-Week Range: $6.77-$19.43
  • Friday's Volume: 1.57 million
  • Three-Month Average Volume: 1.01 million

ImmunoGen  (IMGN) , a biotechnology company, develops targeted anticancer therapeutics. This stock traded up 4.5% to $7.75 in Friday's trading session.

From a technical perspective, ImmunoGen jumped notably higher on Friday right above some near-term support at $6.79 a share with strong upside volume flows. This stock has recently formed a triple bottom chart pattern, after shares found some buying interest at $6.77, $6.83 and $6.79 a share. Following that potential bottom, shares of ImmunoGen have now started to trend higher with some bullish upside volume. Market players should now look for a continuation move to the upside in the short-term if this stock manages to take out Friday's intraday high of $7.78 a share with high volume.

Traders should now look for long-biased trades in ImmunoGen as long as it's trending above those triple bottom support levels and then once it sustains a move or close above Friday's intraday high of $7.78 a share with volume that registers near or above 1.01 million shares. If that move gets underway soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day moving average of $8.27 to $8.34, or even around $8.50 to $9 a share.

Inotek Pharmaceuticals

  • Friday's Range: $6.35-$7.69
  • 52-Week Range: $4.68- $19.45
  • Friday's Volume: 263,000
  • Three-Month Average Volume: 202,248

Inotek Pharmaceuticals  (ITEK) , a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of therapies for glaucoma. This stock traded up 7.4% to $7.62 in Friday's trading session.

From a technical perspective, Inotek Pharmaceuticals surged sharply higher on Friday back above its 20-day moving average of $6.96 a share and its 50-day moving average of $7.31 a share with above-average volume. This high-volume rip to the upside is now quickly pushing shares of Inotek Pharmaceuticals within range of triggering a major breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $8 to $8.20 a share and then above more key resistance at $8.30 to $8.50 a share with high volume.

Traders should now look for long-biased trades in Inotek Pharmaceuticals as long as it's trending above its 20-day moving average of $6.96 a share or above Friday's intraday low of $6.35 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 202,248 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at around $9 to its 200-day moving average of $9.67, or even around $10 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author was long shares of DRNA.

More from Opinion

Tesla's Elon Musk Must Realize He Can't Do It All: Dumbest Thing on Wall Street

Tesla's Elon Musk Must Realize He Can't Do It All: Dumbest Thing on Wall Street

5 Things to Watch for When Netflix Reports Earnings on Monday

5 Things to Watch for When Netflix Reports Earnings on Monday

Flashback Friday: Bank Stocks Stay Hot and Tesla Stays Relevant

Flashback Friday: Bank Stocks Stay Hot and Tesla Stays Relevant

Throwback Thursday: Tesla's Risky, Broadcom Slips, Papa John's Jumps

Throwback Thursday: Tesla's Risky, Broadcom Slips, Papa John's Jumps

Apple's 2018 Macs and iPads Could Prove Strong Enough to Lift Flagging Sales

Apple's 2018 Macs and iPads Could Prove Strong Enough to Lift Flagging Sales